The deals, tied to cases in the US District Court for the District of Delaware, effectively extend US patent protection for VYNDAMAX until June 1, 2031
After Phase 3 results show major hair regrowth gains
The aim is to simplify and strengthen long-term control of airway disease through triple therapy in one device
Former Novo Nordisk and Pharmanovia executive to lead next growth phase in NAD diagnostics and personalised health innovation
On the generics and biosimilars front, the combined business is expected to benefit from Sun’s portfolio of more than 550 approved ANDAs across multiple dosage forms
The submission is backed by positive results from the Phase 3 AFFIRM study
The approval was driven by data from the Phase III TULIP-SC trial
Acquisition to expand the company's women’s health and biosimilars footprint, positioning it among top 25 drugmakers globally
Former Cipla MD & CEO to lead next phase of growth at science-led CDMO platform; Vivek Sharma transitions to advisory role
The study evaluated oral semaglutide in young patients with type 2 diabetes and found it delivered a superior reduction in HbA1c
Subscribe To Our Newsletter & Stay Updated
